Glenmark Pharmaceuticals will receive an upfront payment, milestones, and royalties from Yuhan Corporation as part of a deal that gives Yuhan rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in South Korea, Glenmark said. Specific terms of the deal were not disclosed.
In July 2018, Glenmark announced that Sequirus had acquired the rights to market Ryaltris in Australia and New Zealand. The company says that it “will continue to explore commercial partnerships for Ryaltris in markets where it doesn’t have direct presence.”
Glenmark Chairman and Managing Director Glenn Saldanha commented, “This partnership with Yuhan is in line with our vision to make Ryaltris the first global brand of Glenmark by launching it in several key markets. We are happy to collaborate with Yuhan as it is a strong and reputed player in South Korea and is aligned with Glenmark’s objective to provide quality novel products to fulfill unmet needs of patients.”
Read the Glenmark Pharmaceuticals press release.
